ECM-Affinity Cytokine Conjugates for Tumor-Localized Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy, surgery, and radiation therapy, have limitations in efficacy and toxicity, and direct administration of cytokines for cancer therapy can be toxic systemically, necessitating improved compositions and methods for targeted cytokine delivery to tumors.
Innovation Solution
Development of cytokines operatively linked to extracellular matrix (ECM)-affinity peptides, such as collagen-binding domains, to localize therapy in tumors, reducing systemic exposure and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokines are administered systemically for cancer therapy, then therapeutic efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The cytokine is modified to have different properties in different locations: it retains full activity at the tumor site while being cleared from systemic circulation. This is achieved by attaching the cytokine to a targeting ligand that binds specifically to tumor vasculature, creating local concentration at the tumor while preventing systemic distribution.
Solution Approach 2:
A targeting ligand (such as an antibody or peptide) serves as an intermediary that carries the cytokine to the tumor site. This mediator enables selective delivery by binding to tumor-specific markers or exploiting tumor vasculature characteristics, thereby separating the therapeutic effect from systemic toxicity.
2Reliability
If cytokines are administered at high doses to overcome resistance, then therapeutic efficacy is improved, but side effects increase
Solution Approach 1:
The system creates a local concentration gradient where high cytokine levels are achieved at the tumor site without proportionally increasing systemic levels. The targeting mechanism ensures that the cytokine accumulates preferentially at the tumor, allowing effective local dosing while maintaining safe systemic exposure.
Solution Approach 2:
The targeting ligand acts as a delivery vehicle that concentrates the cytokine at the tumor site, effectively decoupling the dose at the target from the systemic dose. This allows achieving high local concentrations necessary to overcome resistance without proportionally increasing systemic side effects.
3Ease of operation
If standard cancer treatments are used, then ease of administration is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The therapy combines the cytokine with a targeting ligand to create a conjugate that retains the simplicity of cytokine administration while adding tumor-specific targeting capability. This composite structure allows the therapy to be administered systemically like standard treatments but achieves enhanced efficacy through selective tumor accumulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ECM-affinity peptides effectively target and retain cytokines in tumors, enhancing therapeutic efficacy while minimizing systemic toxicity.
Implementation Method 1
An ECM-affinity peptide is one that has affinity for and binds to an extracellular matrix protein, such as collagen
Implementation Method 2
Certain embodiments are directed to the administration of a cancer therapy that localizes in a tumor due to vascular permeability of the tumor
Data Source
AI summary
The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra-or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.